Lipoprotein(a)[
clinical and epidemiological studies by a variety of immunochemical methods. However, lithe, if any, consideration has been given to the confounding effect of the size heterogeneity of apolipoprotein(a) [apo(a)] on the measurement of Lp(a). We developed three direct-binding enzyme-linked immunosorbent assays (ELISAs) with detecting antibodies of different specificities to evaluate the effect of apo(a) size on Lp(a) measurement. The three assays used the same monoclonal antibody to capture the apo(a)-containing particles and were calibrated (in nanomoles per liter) with a serum containing apo(a) with 21 kringle 4 domains. Using all three ELISAs, we measured Lp(a) in a group of 723 subjects selected to have a single apo(a) band, as determined by a high-resolution phenotyping system. Essentially identical results were obtained by the two methods that measured Lp(a) by use of either a polyclonal antibody against apo B or a monoclonal antibody against apo(a) that does not recognize the kringle 4 type 2 repeats. In contrast, the ELISA using a monoclonal antibody specific for apo(a) kringle 4 type 2 repeats overestimated Lp(a) concentration in samples containing apo(a) with more than 21 kringle 4 domains and underestimated Lp(a) samples containing apo(a) with fewer than 21 kringle 4 domains. Thus, these differences in Lp(a) values varied as a function of apo(a) size. We conclude that antibody specificity and apo(a) size heterogeneity can significantly affect Lp(a) measurements.
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Lipoprotein(a)
[Lp(a)1 is a lipoprotein particle formed by the assembly of a low-density lipoprotein (LDL) particle and a carbohydrate-rich, highly hydrophilic protein named apolipoprotein (a) [apo(a)]. 4 In Lp(a), one molecule of apo(a) is covalently linked to the apo B-100 component by a disulfide bridge; the presence of apo(a) distinguishes Lp(a) from all other lipoprotein classes.
Besides high carbohydrate content, which constitutes -30% of the protein mass, apo(a) also exhibits considerable heterogeneity in size and structure (1) . Apo(a) is formed by three distinct structural domains, each exhibiting a high degree of homology with plasminogen (2) . Plasminogen is formed by a protease domain and by five domains called kringles, designated kringle 1 through 5. Each kringle contains six conserved cysteine residues; these form three disulfide bonds that provide the characteristic triple loop structure of the kringles (3). Apo(a) contains an inactive protease domain and one copy of kringle 5 domain-both of which exhibit -85% homology with the corresponding domains of plasminogen-and multiple copies of the plasminogenlike kringle 4 (K4) domain. The multiple copies of apo(a) K4 are similar but not identical to each other and can be divided into 10 distinct kringle types (K4 types 1 through 10); their homology with plasminogen K4 ranges between 78% and 88% (4) . One copy each of K4 type 1 and types 3 through 10 is present per apo(a) particle; K4 type 2, however, is present in a variable number of repeats (from 3 to >40), which are therefore responsible for the size heterogeneity of apo(a) and consequently of Lp(a) (5, 6 
Apo(a) Phenotype Method
The apo(a) size isoforms were determined by a highresolution SDS-agarose gel electrophoretic method followed by immunoblotting, performed as previously reported (14) . Originally, we used a numerical identification system, with no. 1 being the largest identified apo(a) size isoform and 35 the smallest. We recently replaced this arbitrary nomenclature and mow use the number of K4 modified Lp(a). To define the epitope specificity of the MAbs, we immunoblotted them against Lp(a), plasma from a Rhesus monkey, and a series of r-apo(a) species.
On the basis of their epitope specificity, high affinity constant to apo(a), and insensitivity to neuraminidase treatment and oxidation of Lp(a), we selected three MAbs-a-5 (IgG2b), a-6 (IgGl), and a-40 (IgGl)-for use in developing direct-binding ELISA methods for measuring Lp(a). Fig. 1 illustrates the epitope specificity of these MAbs determined by Western blot analysis. The three antibodies failed to react with LDL, plasminogen, or supernatant fluid from mock transfected cells used as control, but all reacted with purified Lp(a); with an r-apo(a) containing 1(4 type 1, eight K4 type 2 repeats, K4 types 3 through 10, kringle 5, and the protease domain; with the same r-apo(a) species but lacking the protease domain; and with plasma from a rhesus monkey (whose apo(a) lacks kringle 5). The results confirm the specificity of the MAbs and indicate that their epitopes are in the K4 region of apo(a). MAb a-S interacted with recombinant proteins corresponding to K4 types 1 and 2, but failed to react with r-apo(a) protein containing a kringle formed by one-third of the amino-terminal of K4 type 1 and two-thirds of the carboxyl-terminal of K4 type S followed by K4 types 6 through 10. MAb a-6 reacted only with recombinant 1(4 type 2; MAb a-40, however, reacted with the r-apo(a) derivative containing the hybrid kringle but showed no interaction with recombinant K4 type 1 or type 2. These results indicate that MAb a-5 is directed to an epitope present in both types 1 and 2 of K4 but not in types 6 through 10. Additionally, MAb a-5 failed to interact with the r-apo(a) containing one-third of the amino-terminal sequence of type 1, indicating that the epitope of MAb a-S is in the middle or the carboxylterminal parts of K4 types 1 and 2. From the amino acid differences between K4 types 1 and 2, we consider that the epitope of MAb a-6 is most probably in the amino-terminal part of type 2. Although the expression of additional single kringle units of apo(a) in mammalian cells is needed to better define the epitope specificity of MAb a-40, we have nonetheless demonstrated that MAb a-40 does not recognize K4 type 2; therefore, the immunoreactivity of this MAb should not be affected by apo(a) size heterogeneity.
Selection of Antibodies to Apo B-i 00
Displacement curves of the binding of PAbs and MAbs against apo B to 1251-labeled Lp(a) by LDL and by Lp(a) preparations having different apo(a) sizes were determined by fluid-phase RIA. A goat PAb against human apo B had the same apparent affinity constant for apo B-100 in Lp(a) and in LDL. Additionally, on a molar basis, the affinity did not change for large or small Lp(a) preparations, which suggests that the variation in apo(a) size does not affect the immunoreactivity of this antibody to apo B in Lp(a). Given the results of these experiments, we selected this PAb for use in the ELISA.
Development of the ELISA Methods
In the first ELISA we developed, MAb a-6 was the capture antibody, and the detection antibody was a-S conjugated to HRP. To evaluate the binding capacity of a-6, we performed parallel analyses of >300 samples having broad range of triglyceride values (0.23-7.46 mmoIIL), using a-6 or a PAb [goat anti-human Lp(a); International Enzymes, Fallbrook, CA] coated to the solid-phase. Practically identical Lp(a) values were observed for the evaluated samples, confirming that MAb a-6 binds apo(a)-containing particles with the same efficiency as a PAb. Repeating these analyses with MAb a-5 as the capture antibody and a-6 conjugated to HRP gave similar results for the evaluated samples. However, because the efficiency of the binding with HRP was higher with a-S we therefore selected a-6 as capture antibody to develop the three ELISA methods with a-S, a-40 and PAb B-100 conjugated to HRP as detecting antibodies. To increase the precision and the comparability of the three ELISAs, we designed them for use with a relatively low dilution of the samples (1:400) and such that the same dilution of the The within-assay CV, determined by 35 measurements of each of the five quality-control samples, ranged from 2.3% to 4.0% and was essentially identical for the three assays. The between-assay CV for the ELISAs with MAb a-S or a-40 ranged from 4.0% to 6.9% whereas that for PAb B-100 ranged from 5.5% to 9.1%. The average CV between duplicate measurements was -4% for each assay.
A fresh-frozen serum sample containing an apo(a) with 21 K4 repeats was used to calibrate the three assays. The Lp(a) value of this serum had been as- Table 1 ). Because the ratio between a-5 and a-40 Lp(a) values was similar to the ratio between the apo(a) size in the samples and in the calibrator (Table  2) Nearly identical Lp(a) values, regardless of apo(a) size, were obtained by the methods using either PAb B-100 antibodies or the MAb specific for K4 domains other than type 2 (Fig. 3, Table 1 ). Linear regression analysis (Fig. 4) (Fig. 3) . Linear regression analysis (Fig. 4) also indicated a less satisfactory correlation (r = 0.945; y = 0.907x + 6.7 nmoli'L) between the MAb a-S and the MAb a-40 methods. 
Discussion
Apo(a), the distinct protein moiety of Lp(a), is heterogeneous in size, both within and between individuals. Additionally, apo(a) in Lp(a) is covalently linked to apo B-100, thereby forming a macromolecular heteroprotein complex. This feature, along with the high amino acid homology of apo(a) with plasminogen, constitutes a serious challenge for the selection and characterization of antibodies in the development of immunoassays to measure Lp(a) in human plasma. The size heterogeneity of apo(a) derives from the variable number of K4 type 2 repeats. Obviously, the immunoreactivity of the antibodies directed to this part of the molecule will vary as a function of the number of the antigenic determinants per particle. The problem of variable immunoreactivity can be circumvented by selecting
MAbs specific for that part of the apo(a) molecule independent of the apo(a) size polymorphism.
Alternatively, because each Lp(a) particle, in addition to apo(a), contains one copy of apo B-100, Lp(a) can be measured by double-antibody ELISA methods in which Lp(a) is immobilized on the solid-phase by antiapo(a) antibodies and quantified by anti-apo B antibodies. However, the selection of antibodies that are not sensitive to variation in apo(a) size does not entirely solve the problem of Lp(a) size heterogeneity.
In fact, because the apo(a):apo B mass ratio varies with the size of Lp(a) particles, antibodies directed to apo B or to nonvariable epitopes of apo(a) will show less immunoreactivity (on a weight basis) to the larger Lp(a) particles than to the smaller Lp(a) particles. This has been clearly shown by Fless et al. (23) , who studied the immunoreactivity of anti-apo B antibodies by using purified Lp(a) particles with different apo(a) isofornis. When Lp(a) protein concentration was expressed on a molar basis, these authors observed a nearly equivalent reactivity for the different Lp(a) preparations. Despite the evident problems of apo(a) size polymorphism, however, numerous immunoassays for Lp(a) have been developed and reported with no characterization of the antibody specificity.
Additionally, because Lp(a) values are traditionally expressed as Lp(a) mass, technical artifacts are produced even in potentially accurate assays such as those based on the measurement of Lp(a):apo B. Our aim in the present work was to quantifr the influence of apo(a) size polymorphism on the accuracy of Lp(a) values. To this end, we selected and extensively characterized our antibodies for their immunochemical properties and domain specificity. To render our assays independent from the variable apo(a):apo B ratio in the different Lp(a) particles, we expressed the Lp(a) protein concentration on a molar basis. We expected that MAb a-40, which does not interact with the variably expressed K4 type 2 of apo(a), and the antibody specific for apo B would be able to measure Lp(a) on equivalent molar basis. Our findings were entirely consistent with this concept, in that essentially identical Lp(a) values, regardless of the apo(a) size, were obtained. To rule out the possibility that conformational changes of uncomplexed apo(a) may result in reduced or abolished immunoreactivity of MAb a-6 or a-40 with the consequence that free apo(a) is not detected by our ELISA method, we conducted experiments with purified r-apo(a). The concentration of the r-apo(a) was quantitatively recovered by our assay (unpublished).
Although a specific epitope may be substantially affected by common sequence variations in apo(a), our finding of no systematic bias between the two independent detection methods in >2000 samples thus far evaluated indicates that the MAb a-40 does not identify a common genetic polymorphism.
It is commonly believed that a single molecule of apo(a) is linked to a molecule of apo B in Lp(a), even though the studies by Fless et al. (25) seem to indicate that two molecules of apo(a) are linked to apo B. We do not have evidence from our data to support one or the other hypothesis, but our findings strongly suggest that the molar ratio of apo B to apo(a) is constant: Not a single individual among those examined gave results in which the Lp(a) measured by apo(a) detection was twice that measured by apo B detection. Because Lp(a) is known to form complexes with LDL and other apo B-containing lipoproteins that are enriched in triglyceride In contrast to the nearly identical results obtained by MAb a-40 and PAb B-100, the Lp(a) values obtained by MAb a-S clearly reflected the different immunoreactivity of this MAb for the various apo(a) size polymorphs. In fact, our findings indicate that the bias between the two apo(a)-specific ELISAs, one using a MAb directed to the invariant portion of the K4 domain (MAb a-40) and the other using a MAb directed to the variable repeats (MAb a-5), was strictly dependent of the apo(a) size in the samples. Lp(a) values were overestimated by MAb a-5 in samples with large Lp(a) particles and underestimated in those with small Lp(a) particles. The high correlation (r = 0.967) between the degree of bias and the apo(a) size of the samples clearly documents the significant effect of apo(a) size heterogeneity on the measurement of Lp(a). In evaluating to what extent this apo(a) size-dependent variability of Lp(a) values obtained by MAb a-5 would impair the ability to correctly classiIr subjects through their Lp(a) values as being or not being at increased risk for coronary artery disease, we used an arbitrary cutpoint of the 80th percentile Lp(a) value obtained with the two apo(a) size-insensitive methods (those using MAb a-40 and PAb B-100). Thirty-eight of the 723 subjects (5.1%), would be considered at increased risk based on MAb a-5 values (false positive), and 80 subjects (11%), would not be considered at risk (false negative).
However, our evaluation was performed with subjects having a single apo(a) isoform, a group that constitutes -20% of the general population (14).
Therefore, for an accurate estimate of the magnitude of the misclassification, the evaluation should be performed with a large number of subjects representative of the distribution of apo(a) size isoforms in the general population.
This study is currently being performed in our laboratory.
In conclusion If sound evidence of the clinical significance of Lp(a) is to be achieved, a major effort is required to validate and standardize the assays used in clinical and epidemiological studies.
